Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies

Current Oncology

Volumn 14, Issue 2, 2007, Pages 66-69

  Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cancer treatment; cMet; Hepatocyte growth factor; Targeting

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA CATENIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; NEUTRALIZING ANTIBODY; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; RAC PROTEIN; RHO FACTOR; RIBOZYME; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; STAT3 PROTEIN; WNT PROTEIN;

ARTICLE; CANCER CELL; CANCER GENETICS; CANCER THERAPY; FIBROSARCOMA; GENE CONTROL; HEMATOLOGIC MALIGNANCY; HUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 51649128339     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.108     Document Type: Article

References (31)

1. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
2. Gherardi E, Stoker M. Hepatocyte and scatter factor. Nature 1990;346:228.
3. Jiang WG, Parr C, Martin TA, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005;53:35-69.
4. Jiang WG, Davies G, Martin TA, et al. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med 2005;16:723-8.
5. Kajiya K, Hirakawa S, Ma BJ, Drinnenberg I, Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005;24:2885-95.
6. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor - stromal interactions. Int J Cancer 2006;119:477-83.
7. Wojcik EJ, Sharifpoor S, Miller NA, et al. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 2006;25:2773-84.
8. Giannini G, Noel J. Constitutive hepatocyte growth factor - receptor (HGF R)/met tyrosine kinase activation is associated with cellular transformation independently of mutations within its tyrosine kinase and C-terminal domains (abstract). Mol Biol Cell 2002;13(suppl):875a.
9. Tjin EP, Groen RW, Vogelzang I, et al. Functional analysis of HGF/ met signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006;107:760-8.
10. Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2006;[in press].
11. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. met-Regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-95.
12. Hiscox S, Jiang WG. Association of the HGF/SF receptor, c-Met, with the cell-surface adhesion molecule, E-cadherin and catenins in human tumor cells. Biochem Biophys Res Commun 1999;261:406-11.
13. Davies G, Jiang WG, Mason MD. HGF/SF modifies the interaction between c-Met and E-cadherin/catenin complex in prostate cancer cells. Int J Mol Med 2001;7:385-8.
14. Rasola A, Fassetta M, De Bacco F, et al. A positive feedback loop between hepatocyte growth factor receptor and •- catenin sustains colorectal cancer cell invasive growth. Oncogene 2007;26:1078-87.
15. Bauer TW, Somcio RJ, Fan F, et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 2006;5:1676-82.
16. Fischer OM, Giordano S, Comoglio PM, Ullrich A. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 2004;279: 28970-8.
17. Hecht M, Schulte JH, Eggert A, Wilting J, Schweigerer L. The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness. Carcinogenesis 2005;26: 2105-15.
18. Pante G, Thompson J, Lamballe F, et al. Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/met-induced cell migration and neurite growth. J Cell Biol 2005;171:337-48.
19. Stella MC, Trusolino L, Pennacchietti S, Comoglio PM. Negative feedback regulation of met-dependent invasive growth by NOTCH. Mol Cell Biol 2005;25:3982-96.
20. Lee CC, Putnam AJ, Miranti CK, et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 2004;23:5193-202.
21. Leibowitz-Amit R, Tsarfaty G, Abargil Y, Yerushalmi GM, Horev J, Tsarfaty I. Mimp, a mitochondrial carrier homologue, inhibits met-HGF/SF-induced scattering and tumorigenicity by altering met-HGF/SF signaling pathways. Cancer Res 2006; 66:8687-97.
22. Herter S, Piper DE, Aaron W, et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 2005;390:125-36.
23. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (Hai-1B) and Hai-2. FEBS Lett 2005;579:1945-50.
24. Nagakawa O, Yamagishi T, Fujiuchi Y, et al. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur Urol 2005;48:686-90.
25. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004;10:202-11.
26. Kankuri E, Cholujova D, Comajova M, Vaheri A, Bizik J. Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Res 2005;65:9914-22.
27. Morris MR, Gentle D, Abdulrahman M, et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res 2005;65:4598-606.
28. Hay RV, Cao B, Skinner RS, et al. Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/ scatter factor. Mol Imaging 2002;1:56-62.
29. Hay RV, Cao B, Skinner RS, et al. Nuclear imaging of met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res 2005;11(pt 2):7064s-9s.
30. Shaharabany M, Abramovitch R, Kushnir T, et al. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res 2001;61:4873-8.
31. Athauda G, Giubellino A, Coleman JA, et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 2006;12(pt 1):4154-62.